mRNA Flu Vaccine Deal Promises Global Equity

A significant partnership has been formed to develop and distribute mRNA flu vaccines globally, aiming to prevent a repeat of 'vaccine nationalism'. CEPI, the Coalition for Epidemic Preparedness Innovations, has committed £40m to fund trials for a new mRNA flu vaccine. As part of this agreement, Moderna will ensure rapid and affordable access to the vaccine for lower and middle-income nations during any future pandemic.

This development comes after the US government reduced its funding for mRNA vaccines by $500m in August 2025. The decision, influenced by the health secretary's skepticism about mRNA technology's risks for respiratory viruses, highlights a divergence in approach. The new flu vaccine technology offers a rapid production capability, with an initial capacity of 100 million doses annually, extendable to 250 million in a pandemic scenario, a stark contrast to traditional egg-based methods which can be vulnerable to highly virulent strains.